Beckham-backed Prenetics stops Bitcoin buying, eyes up to $200 million IM8 revenue

Beckham-backed Prenetics stops Bitcoin buying, eyes up to $200 million IM8 revenue

NEW YORK, December 30, 2025, 10:25 ET

  • Prenetics said it stopped daily bitcoin purchases on Dec. 4 and will not buy more, keeping 510 BTC as a reserve.
  • The company said it will focus capital on IM8 and forecast fiscal 2026 revenue of $180 million to $200 million.

Prenetics Global Ltd said on Tuesday it has stopped buying bitcoin and will not make additional purchases, redirecting its capital allocation to its IM8 health supplement brand. The Nasdaq-listed health sciences company said it halted daily buying on Dec. 4 and will keep its 510 bitcoin as a treasury reserve asset.

The decision marks a pullback from a bitcoin treasury strategy — where a company holds the cryptocurrency as part of its cash reserves — that can quickly reshape balance sheets when prices swing. Bloomberg described Prenetics as the latest firm to halt such purchases amid depressed crypto prices.

Prenetics is betting those resources will produce steadier returns in IM8, which it said passed $100 million in annualized recurring revenue — a run-rate measure often used for subscription-style sales — within 11 months. It forecasts fiscal 2026 IM8 revenue of $180 million to $200 million.

Chief Executive Danny Yeung said the “phenomenal success of IM8 has exceeded all expectations.” Prenetics said it had more than $70 million in cash and cash equivalents, 510 bitcoin and no debt. markets.businessinsider.com

The company said it will not allocate any existing or new capital to buy more bitcoin and will instead channel spending into IM8’s growth, including product development and international expansion.

Prenetics shares were up about 1% at $16.44 in morning trade. Bitcoin was up about 0.8% at around $88,224.

The pivot follows a short run in which Prenetics promoted a “dual-engine” approach pairing IM8 expansion with routine bitcoin accumulation. In an Oct. 31 release, Prenetics said it was buying one bitcoin per day and held 378 bitcoin after purchasing 100 at an average price of $109,594. Investing News Network (INN)

Days earlier, Prenetics completed a $44 million equity offering and said it would use proceeds to fund IM8 expansion and bitcoin accumulation. Investing.com reported the company held 275 bitcoin as of Oct. 27.

Strategy, formerly known as MicroStrategy, has gone the other way, continuing to raise money and buy bitcoin, making it the most prominent example of the corporate-treasury trade. MarketWatch reported the software company has used share sales this month to fund additional purchases.

Semler Scientific, another U.S.-listed healthcare company, says on its website that it concluded investing in bitcoin was the best use of cash after studying alternatives.

Prenetics said it will keep its existing bitcoin holdings as a reserve asset while concentrating management attention on scaling IM8. The company said the strategy change aligns it more closely with shareholder priorities as it expands the brand.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

US Stock Market Today Updates

MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.
Why Caterpillar stock is riding an AI data-center generator boom
Previous Story

Why Caterpillar stock is riding an AI data-center generator boom

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade
Next Story

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade